2022 AACR Annual Meeting Participation

Friday, April 8

E-Poster Sessions

**OPO.BCS01.01 – Bioinformatics and Computational Biology**

5026 - Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S14001 trial) with outcomes in squamous cell lung cancer
Authors: Roy S. Herbst; Scott Gettinger
Session: April 8; 12:00 – 1:00 PM
Location: E-Poster Website

**OPO.IM02.01 – Preclinical Immunotherapy**

5533 - YIV-906 could modulate nuclear factor of activated T-cells (NFAT) activity of T cells for immune checkpoint blockade therapy and CAR T-cell therapy
Presenter/Authors: Wing Lam, Shwu-Huey Liu, Peikwen Cheng, Yung-Chi Cheng
Session: April 8; 12:00 – 1:00 PM
Location: E-Poster Website

**OPO.PS01.01 – Population Sciences**

5882 - Birth characteristics and risk of early-onset myeloproliferative neoplasms in a population-based case-control study
Presenter/Author: Nikolai A. Podoltsev; Xiaomei Ma
5897 - Paired tumor/normal clinical sequencing enables identification of patients with pathogenic germline variants
Presenter/Authors: Christina N. Dimopoulos, Karina Brierley, Joanna Gibson, Zenta Walther, Xavier Llor
Session: April 8; 12:00 – 1:00 PM
Location: E-Poster Website

Educational Session

**ED003 – Predictive Biomarkers for Immunotherapy**

*Introduction to biomarkers in the adjuvant setting: Predictive vs. prognostic*
Presenter/Speaker: David L. Rimm
Session: April 8; 5:00 – 5:20 PM
Location: New Orleans Theater B, Convention Center

Methods Workshop

**MW008 – Spatial Transcriptomics and Cellular Imaging analysis of the Tumor Microenvironment**

*Spatially resolved multi-omics sequencing at genome scale and cellular level*
Presenter/Speaker: Rong Fan
Session: April 8; 6:00 – 6:20 PM
Location: La Nouvelle Orleans A-B, Convention Center

Educational Session

**ED042 – Sex Matters: Understanding the Effect of Sex on Shaping the Tumor and Response to Cancer Therapy**

*Sex-specific differences in metabolism, microbiome and cancer*
Saturday, April 9

Educational Session
ED037 - Roles of RNA in Cancer and Cancer Therapies
Targeting altered RNA expression and splicing in cancer
Speaker: Luisa Escobar-Hoyos, PhD
Session: April 9; 1:00 – 1:20 PM
Location: New Orleans Theater A, Convention Center

Sunday, April 10

Plenary Session
PL02 - Opening Plenary Session: Decoding Cancer Complexity, Integrating Science, Transforming Patient Outcomes
Genotoxic Gut Bacterial Metabolites And Their Roles In Colorectal Cancer Initiation
Speaker: Jason M. Crawford
Session: April 10; 10:10 – 10:35 AM
Location: Hall B-C, Convention Center

Poster Sessions
PO.CH01.01 – Nanotechnology Drug Delivery
294 / 2 – Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
Presenter/Authors: Matthew Murray, Yazhe Wang, Ranjini K. Sundaram, Jason Beckta, W. Mark Saltzman, Ranjit S. Bindra
Session: April 10; 1:30 – 5:00 PM
Location: Section 20

PO.ET03.02 – Cancer Drug Resistance and Reversal of Resistance
392 / 2 – Novel therapeutics that overcome MMR-mediated temozolomide resistance and retain therapeutic index in GBM
Presenter/Author: Kingson Lin
Session: April 10; 1:30 – 5:00 PM
Location: Section 25

Clinical Trials Minisymposium
CTMS01 – Biomarker Advances in Clinical Trials
Chairperson: Kurt A. Schalper
Session: April 10; 3:00 – 5:00 PM
Location: Great Hall BC, Convention Center

Clinical Trials Plenary Session
CTPL02 – Clinical Trials Targeting the DNA Damage Response and KRAS
Discussant: Patricia M. LoRusso
Session: April 10; 3:00 – 5:00 PM
Location: Great Hall AD, Convention Center

Minisymposiums
MS.ET03.01 – Elucidating Disease Biology and Drug Resistance Mechanisms
Co-Chairperson: Katerina A. Politi
Session: April 10; 3:00 – 5:00 PM
Monday, April 11

**Poster Sessions**

**PO.CL11.07 – Biomarkers Predictive of Therapeutic Benefit 2**

1256 / 3 – **B-cell infiltration in association with survival outcomes in nivolumab-treated head and neck squamous cell carcinoma (HNSCC): NCT 03652142**

Presenter/Author: Niki Gavrielatou

Session: April 11; 9:00 AM – 12:30 PM

Location: Section 31

**PO.CT02.01 – Phase II Clinical Trials 1**

CT111 / 8 – **Phase 1/2 study of pepinemab, an inhibitor of semaphoring 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84)**

Author: Barbara Burtness

Session: April 11; 9:00 AM – 12:30 PM

Location: Section 33

**PO.ET03.03 – Lung Cancer Treatment Resistance**

1094 / 7 – **SMARCA4-mediated chromatic remodeling regulates Osimertinib resistance in EGFR-mutant lung adenocarcinoma**

Presenter/Authors: Fernando J. De Miguel, Wesley L. Cai, Mary Ann Melnick, Camila Robles-Oteiza, Anna Wurtz, Maria I. Toki, David L. Rimm, Robert Homer, Don X. Nguyen, Katerina A. Politi

Session: April 11; 9:00 AM – 12:30 PM

Location: Section 23

**PO.IM01.04 – Molecular Signaling and Metabolic and Epigenetic Regulation on Adaptive Tumor Immunity**

1357 / 16 – **T cell memory and the critical effectors of successful anticancer immune response**

Presenter/Authors: William Damsky, Meaghan McGeary, Akiko Iwasaki, Marcus Bosenberg

Session: April 11; 9:00 AM – 12:30 PM

Location: Section 37

**PO.IM01.05 – Tumor Antigens, Antigen Presentation, and Tumor Immunity**

1379 / 10 – **Discovery of tumor-associated, immunogenic peptides presented in a patient-derived, mutant calreticulin-driven myeloproliferative neoplasm cell line**

Presenter/Author: Najila Arshad, Peter Cresswell

1380 / 11 – **Setdb1-loss reactivated ERV expression and interferon signaling to induce immune-mediated melanoma clearance**

Presenter/Authors: Meaghan K. McGeary, William Damsky, Drew Daniels, Goran Micevic, Eric Song, Hua Jane Lou, Clotilde Calderwood, Sateja Paradkar, Akiko Iwasaki, David Calderwood, Benjamin Turk, Marcus Bosenberg

Session: April 11; 9:00 AM – 12:30 PM
Rational combinations with the dual RAF/MEK inhibitor VS6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations

Authors: Antonella Bacchiocchi, Mario Sznol, Ruth Halaban
Session: April 11; 9:00 AM – 12:30 PM
Location: Section 27

Major Symposia
SY17 - Targeted Protein Degradation: Exploring New Targets and E3 Ligases
Chairperson: Craig M. Crews
Session: April 11; 12:30 – 2:00 PM
Location: Room 220-222, Convention Center

SY20 - KRAS Anniversary Session: Novel Mechanisms for Targeting KRAS
The clinical successes and challenges of drugging KRAS
Chairperson and Presenter: Patricia M. LoRusso
Session: April 11; 12:30 – 2:00 PM
Presentation: 1:28 – 1:45 PM
Location: Hall B-C, Convention Center

Poster Sessions
PO.CL06.03 – Immune Response to Therapies/Immune Monitoring and Clinical Correlates
Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400 trial
Authors: Roy S. Herbst; Scott Gettinger
Session: April 11; 1:30 – 5:00 PM
Location: Section 31

PO.CL11.09 – Spatial Proteomics and Transcriptomics
Spatial omics and multiplexed imaging to discover new biomarkers of response or resistance to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC)
Presenter/Authors: Myrto Moutafi, Sandra Martinez-Morilla, Rolando Garcia-Milian, Thazin Nwe Aung, Ioannis Vathiotis, Niki Gavrielatou, Vasiliki Xirou, Leonidas Salichos, David L. Rimm
Location: Section 34

PO.CT02.02 – Phase II Clinical Trials 2
A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and esophageal junction adenocarcinoma (GEJ)
Presenter/Authors: Michael Cecchini, Joseph Chao, Yu Shyr, James Cleary, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristin Spencer, Edward Kim, Chih-Yuan Hsu, Stacey Stein, Jaykumar Thumar, Jeremy Kortmansky, John Kunstman, Patricia LoRusso, Percy Ivy, Jill Lacy
Session: April 11; 1:30 – 5:00 PM
Location: Section 36

PO.ET02.01 – Mechanisms of Drug Action 1
RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors
Author: Patricia LoRusso
PO.MCB10.01 – Short and Long Noncoding RNA Regulating Cancer Biology
1540 / 9 – Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancer
Presenter/Authors: Elena Martínez-Terroba, Fernando J. De Miguel, Camila Robles-Oteiza, Katerina Politi, Nadya Dimitrova
Session: April 11; 1:30 – 5:00 PM
Location: Section 7

PO.TB06.11 – Tumor Immune Profiling and Spatial Analysis
1722 / 19 – Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)
Presenter/Authors: Miguel Lopez de Rodas Gregorio, Lindsey Behlman, David L. Rimm, Roy S. Herbst, Anant Madabhushi, Jonathan W. Riess, Vamsidhar Velcheti, Matthew Hellmann, Justin F. Gainor, Kurt A. Schalper
Session: April 11; 1:30 – 5:00 PM
Location: Section 15

Minisymposiums
MS.TB01.01 – Next-Gen Genetically Engineered Mouse Models
Co-Chairperson: Katerina A. Politi
Session: April 11; 2:30 – 4:30 PM
Location: Room 278-282, Convention Center

MS.IM02.02 – Cancer Biology and Tumor Immunity
2166 – Ibuprofen induces ferroptosis to potentiate antitumor immunity
Presenter/Authors: Ronan Talty, Michelle Ferreira, Irina Krykbaeva, Marcus Bosenberg
Session: April 11; 4:05 – 4:20 PM
Location: New Orleans Theater A, Convention Center

Major Symposium
DC01 - Supporting Smoking Cessation Among Patients with Cancer Who Use Tobacco Products
Chairperson: Roy S. Herbst, MD, PhD
Session: April 11; 3:00 – 4:30 PM
Location: TBA

Forums
FO07 - Untangling Mechanisms of Sensitivity and Resistance to Immune Checkpoint Blockade
Decoding the Role Of The Tumor Microenvironment In Immune Evasion And Therapeutic Resistance Through Multi-Dimensional Analysis And Data Integration
Presenter: Kurt A. Schalper
Session: April 11; 5:32 – 5:44 PM
Location: Great Hall AD, Convention Center

FO12 – Dharma Master Jiantai Forum on Advances in Lung Cancer
Moderator: Roy S. Herbst, MD, PhD
Session: April 11; 5:00 – 6:30 PM
Location: New Orleans Theater B, Convention Center

Tuesday, April 12
Poster Sessions
PO.CT01.02 – Phase I Clinical Trials 2
**CT188 / 13 – ICT01, an anti-butyrophilin 3A targeted mAb activating g9d T cells, induces immune remodeling of the tumor microenvironment and clinical responses on combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial**

Author: Patricia LoRusso
Session: April 12; 9:00 AM – 12:30 PM
Location: Section 33

**PO.ET06.09 – Cell Cycle, Replication Inhibitors, and Immunotherapy Agents**

**2580 / 19 - Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: an immune biomarker analysis of Phase III SWOG LungMAP S1400I trial**

Authors: Roy S. Herbst; Scott Gettinger
Session: April 12; 9:00 AM – 12:30 PM
Location: Section 21

**PO.MCB08.02 - Tumor-associated Metabolic Changes**

**2394 / 23 - Discovery of a sex-specific metabolic phenotype in KRAS mutant colorectal cancer**

Presenter/Authors: Hong Yan, Yuping Cai, Xinyi Shen, Abhishek Jain, Philip B Paty, Marcus Bosenberg, Sajid A Khan, Caroline Johnson
Session: April 12; 9:00 AM – 12:30 PM
Location: Section 8

**Clinical Trials Plenary Session**

**CTPL04 - Combination Immunotherapy Clinical Trials**

Discussant: Mario Sznol
Session: April 12; 10:31- 10:41 AM
Location: Hall B-C, Convention Center

**Major Symposium**

**DC01 - Supporting Smoking Cessation Among Patients with Cancer Who Use Tobacco Products**

Chairperson/Speaker: Roy S. Herbst
Session: April 12; 10:15 – 11:45 AM
Location: Room 356-357, Convention Center

**Poster Sessions**

**PO.ET09.01 - Preclinical Radiotherapeutics**

**3312 / 10 - A CRISPR-Cas9 screen in meningioma reveals GCN2/ATF4 is a novel target that enhances the response to radiation**

Presenter/Authors: Marta Baro, Murat Gunel, Jennifer Moliterno, Joseph N. Contessa

**3315 / 13 - CRISPR-Cas9 screening reveals novel targets that govern HNSCC response to radiation therapy**

Presenter/Authors: Vanessa M. Kelley, Marta Baro, Aanchal Katoch, Chatchai Phoomak, Hojin Lee, Joseph Contessa
Session: April 12; 1:30 – 5:00 PM
Location: Section 25

**PO.MCB05.02 - Chromatin Modifiers: From Mechanism to Therapeutic Opportunity**

**2970 / 18 - Oncometabolites confer vulnerabilities in NAD biosynthesis via NAPRT gene silencing**

Presenter/Authors: Katelyn Noronha, Jiayu Liang, Ranjit Bindra
Session: April 12; 1:30 – 5:00 PM
Location: Section 3

**Clinical Trials Minisymposium**

**CTMS03 - Immunotherapy Combination Strategies in Clinical Trials**
**CT040 - SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial**

Author: Patricia LoRusso
Session: April 12; 3:50 – 4:00 PM
Location: La Nouvelle Orleans A-B, Convention Center

**Wednesday, April 13**

**Poster Sessions**

**PO.CL06.06 - Vaccines / Immunomodulatory Agents and Interventions**

*4151 / 5 - Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors*

Author: Patricia LoRusso
Session: April 13; 9:00 AM – 12:30 PM
Location: Section 34

**PO.ET04.01 - Identification of Molecular Targets**

*3981 / 3 - Targeting SRP receptor-beta reduces protein glycosylation and cell growth in lung cancer*

Presenter/Authors: Chatchai Phoomak, Joseph N. Contessa

*3994 / 16 - ER stress is a major pathway responsible for the osteosarcoma sensitivity to OST inhibition*

Presenter/Authors: Aanchal Katoch, Joseph Contessa.
Session: April 13; 9:00 AM – 12:30 PM
Location: Section 24

**Advances in Diagnostics and Therapeutics**

**ADT13 - Machine Learning to Translate the Cancer Genome and Epigenome into Biological and Clinical Insights**

*Limitations Of Machine Learning, Cancer Biology As A Combinatorial Challenge*

Chairperson/Presenter: Lajos Pusztai
Session: April 13; 10:15 – 11:45 AM
Location: New Orleans Theater A, Convention Center

**Advances in Population Sciences**

**APS03 - Functional Role of Long Tail Coding and Non-coding Mutations in Cancer**

Chairperson/Speaker: Mark Gerstein
Session: April 13; 10:15 – 11:45 AM
Location: New Orleans Theater C, Convention Center